Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026)

Publication | Closed Access

DOI

Citations

References

2022

Year

Richard T. Penson, Ricardo Villalobos-Valencia, Nicoletta Colombo, Charles A. Leath, Mariusz Bidziński, Jae‐Weon Kim, Joo‐Hyun Nam, Radosław Mądry, Carlos Hernández, Paulo Mora,

Gynecologic Oncology

Olaparib MonotherapyMedicineCancer ManagementPhase Iii TrialGynecologyCancer TreatmentOncologyRadiation OncologyGynecology OncologyMolecular OncologyGermline Brca1Ovarian Cancer